lösning.

DRUG5 trials

Sponsors

Tiohundra AB, Karolinska University Hospital, Vastra Gotalandsregionen, Region Skane

Conditions

Cardiac arrestChronic coronary syndromeNon-metastatic HER2-positive Breast CancerTakotsubo syndrome

Phase 2

A Randomized Trial of Trastuzumab Deruxtecan and Biology-Driven Selection of Neoadjuvant Treatment for HER2-positive Breast Cancer: ARIADNE

RecruitingCTIS2022-501504-95-00

Karolinska University HospitalNon-metastatic HER2-positive Breast Cancer

Start: 2023-06-23Target: 402Updated: 2025-08-18

Phase 3

Vasopressin and Steroids in addition to Adrenaline in cardiac arrest -a randomized clinical trial

WithdrawnCTIS2022-500137-89-00

Tiohundra ABCardiac arrest

Start: 2022-12-19Target: 1400Updated: 2022-09-02

Vasopressin and Steroids in addition to Adrenaline in cardiac arrest -a randomized clinical trial

SuspendedCTIS2025-521283-35-00

Tiohundra ABCardiac arrest

Start: 2025-04-02Target: 1400Updated: 2025-04-02

Phase 4

Optimized pharmacological treatment for broken heart (takotsubo) syndrome

RecruitingCTIS2022-501874-21-00

Vastra GotalandsregionenTakotsubo syndrome

Start: 2020-12-15Target: 1600Updated: 2025-05-16

HYPER-trial Hyperemic mYocardial Perfusion by adEnosine at diffeRent doses

RecruitingCTIS2023-505248-20-00

Region SkaneChronic coronary syndrome

Start: 2024-10-14Target: 180Updated: 2024-03-05

Related Papers

Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNE

BMJ Open2025-08-011 citations

Machine learning-based spatial characterization of tumor-immune microenvironment in the EORTC 10994/BIG 1-00 early breast cancer trial.

2025-03-073 citations